All News
Vaccine Efficacy in Patients with Seronegative Spondyloarthritis
Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
Read Article
Eder et al. New PRESTO prediction model for PsA development in PsO. 1 year and 5 year models presented @RheumNow #ACR22 Abstr#1612 https://t.co/xMMVaIGnN5 https://t.co/RlJ3ZlEeDE
Richard Conway RichardPAConway ( View Tweet)
Krijbolder et al. TREAT EARLIER DBRCT. MTX vs PBO for pre-RA. Treat 1 year, stop, and follow 1 year. No difference in RA development. Delay in ACPA+ or high risk. Sustained benefit in MTX group on pain, EMS, function, MRI. @RheumNow #ACR22 Abstr#1603 https://t.co/M2qQfgrhC1 https://t.co/UUeknTLx0K
Richard Conway RichardPAConway ( View Tweet)
Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6
Richard Conway RichardPAConway ( View Tweet)
Bihlet et al. Anti-histamines may reduce structural progression of knee OA. Post-hoc analysis of 2 trials @RheumNow #ACR22 Abstr#1893 https://t.co/RrrelHDz75 https://t.co/Sf7RpjjAaN
Richard Conway RichardPAConway ( View Tweet)
Post-hoc analysis of SELECT-COMPARE showing decreased residual pain at week 12 but not week 26 cf. ADA, regardless of residual inflammation. Does this just reflect differing onset of action?
@RheumNow ABST0297 #ACR22
https://t.co/9WyZAN3B16 https://t.co/fAC1bLw9EB
Julian Segan JulianSegan ( View Tweet)
Shanahan et al. RCT of Genicular nerve block for knee OA. It works but temporary, with loss of effect by week 12. @RheumNow #ACR22 Abstr#1892 https://t.co/VySjBGrVeR https://t.co/JNKQeOVB6z
Richard Conway RichardPAConway ( View Tweet)
In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than other DMARDs which were continued (mostly RTX/MMF).
Good to see more direct data rather than having to extrapolate from flu.
@RheumNow ABST0913 #ACR22
https://t.co/YphKywNJfA
Julian Segan JulianSegan ( View Tweet)
Please find our Day 2 #ACR22 Daily Recap Video by @RheumNow Faculty
https://t.co/f3BbKkgzRp
@Janetbirdope @synovialjoints @doctorRBC @bella_mehta @AkhilSoodMD @RHEUMarampa @DrCassySims https://t.co/VZM53cUyWL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Ho et al. Consistent colchicine use assoc reduction in MACE in patients with gout and pre-existing CVD. @RheumNow #ACR22 Abstr#1815 https://t.co/tXwa2FrSrp https://t.co/8TKl4z7iaH
Richard Conway RichardPAConway ( View Tweet)
Kastrati et al. Case series immune apheresis in IIM. 24 patients. Reduced CK in 21/24, 971 to 347. Reduced steroid 25%, median 12.5mg reduction @RheumNow #ACR22 Abstr#1882 https://t.co/UUlm4xEX61 https://t.co/bS2IA9OKnH
Richard Conway RichardPAConway ( View Tweet)
"If your partner won't use protection, close the vault!" - Dr. J Patricia Dhar interviewed on sexual Health and STD Prevention in Lupus Patients. Contact her pdhar@med.wayne.edu if you want to collaborate or fund her studies. #ACR22 @rheumnow https://t.co/WDLq9Mhoiw
TheDaoIndex KDAO2011 ( View Tweet)
Does curcurmin (tumeric) do anything in RA?
Big talk & sales.
Best chance would be keeping pts in remission during csDMARD taper:
DBRCT n=200
52w, high bioavail form, good serum conc
Absolutely nothing vs placebo
I'll call it: just doesn't work in RA
ABST1587 #ACR22 @RheumNow https://t.co/wecEfkXT55
David Liew drdavidliew ( View Tweet)
Flood @FloodRachael et al. ULT reduces non-episodic foot pain in hyperuricaemic patients who fail to meet gout classification criteria. Predicted by double counter or tophus on US. @RheumNow #ACR22 Abstr#1828 https://t.co/iOy0Vo5HVO https://t.co/vF98DFB7hJ
Richard Conway RichardPAConway ( View Tweet)
McCormick et al Fruit juice and other sugar-sweetened drinks increase gout flare in dose-dependent manner @RheumNow #ACR22 Abstr#1805 https://t.co/aGg5i5XyTK https://t.co/x8ChwASM6P
Richard Conway RichardPAConway ( View Tweet)
A Novel Treatment Response Measurement Tool for Lupus
Dr. Dao discusses abstract 2054 with Dr. Morand at the #ACR22 Convergence. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
https://t.co/iqqyI953Vz https://t.co/taUjTHsrJ2
Links:
Dr. John Cush RheumNow ( View Tweet)
Even young SLE patients are still at high risk of severe COVID:
- in general pop, age is key factor
- in SLE, risk is high across age groups (maybe due to both meds & disease)
- vaccination makes a big diff but SLE pts still at high risk
ABST1591 @CCalabreseDO #ACR22 @RheumNow https://t.co/ra1F79ITn3
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Abstr#1830 Short attack of arthritis episode is common in Familial Mediterranean Fever. Other pointers? A cohort study in Turkey showed to consider FMF in pts with red mono-oligo arthritis in lower limbs & spondyloarthropathy. 20% were colchicine resistant @RheumNow https://t.co/JXGcgCrhPu
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#1839 "Doctor, I have fever & recurrent right-sided tummy pain, is it my appendix?" A case-control study in Turkey reported 16% of unindicated appendectomies prior to FMF diagnosis. This group had late diagnosis and associated with M694V homozygous mutation @RheumNow https://t.co/QtxjuHDXYC
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)